Analytical Data
-
Gene name
FRG1
- Application
-
Alternative Names
frg1; FRG1_HUMAN; FRG1A; FSG1; FSHD region gene 1 protein; Protein FRG1
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q14331
-
Expression Region
1-258aa
-
AA Sequence
MAEYSYVKSTKLVLKGTKTKSKKKKSKDKKRKREEDEETQLDIVGIWWTVTNFGEISGTIAIEMDKGTYIHALDNGLFTLGAPHKEVDEGPSPPEQFTAVKLSDSRIALKSGYGKYLGINSDGLVVGRSDAIGPREQWEPVFQNGKMALLASNSCFIRCNEAGDIEAKSKTAGEEEMIKIRSCAERETKKKDDIPEEDKGNVKQCEINYVKKFQSFQDHKLKISKEDSKILKKARKDGFLHETLLDRRAKLKADRYCK
-
Molecular Weight
54.12 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FRG1, or Farnesylated Rab GTPase 1, is a protein that has gained attention in recent years due to its association with certain biological processes and diseases. Initially identified in studies related to muscle development and function, FRG1 is believed to play a crucial role in signaling pathways that govern cell growth, differentiation, and survival. Research indicates that mutations or dysregulation of FRG1 may contribute to pathological conditions, particularly in neuromuscular disorders such as facioscapulohumeral muscular dystrophy (FSHD). The exploration of FRG1 as a recombinant protein has opened avenues for understanding its structure-function relationships, interaction with other cellular components, and its potential role in therapeutic interventions. By utilizing techniques in protein engineering and molecular biology, researchers aim to elucidate the mechanistic underpinnings of FRG1's action, providing insights that could lead to novel treatments for diseases linked to its dysfunction. The recombinant expression of FRG1 also enables the development of high-throughput screening assays, facilitating the discovery of small molecules or biologics that may modulate its activity. As the scientific community continues to uncover the complexities surrounding FRG1, its significance in both basic research and clinical applications becomes increasingly evident, marking it as a critical focus in the field of molecular biology and medicine.
